Free US stock put/call ratio analysis and sentiment contrarian indicators for market timing signals. We monitor options market activity to understand when markets might be too bullish or bearish.
This analysis evaluates Biogen Inc.’s (NASDAQ: BIIB) recently announced definitive licensing agreement with TJ Biopharma for Greater China rights to experimental antibody felzartamab, a key late-stage asset in the firm’s immunology pipeline. The $850 million total potential deal unlocks full global
Biogen Inc. (BIIB) - Secures Exclusive Global Felzartamab Rights via Greater China Licensing Deal, Shares Rally - Community Breakout Alerts
BIIB - Stock Analysis
4341 Comments
806 Likes
1
Azaia
Registered User
2 hours ago
My brain processed 10% and gave up.
👍 289
Reply
2
Quil
Daily Reader
5 hours ago
This feels like something I should agree with.
👍 70
Reply
3
Lanetta
Loyal User
1 day ago
Comprehensive US stock earnings whisper numbers and actual versus estimate analysis to identify surprises before they happen. Our earnings surprise analysis helps you anticipate positive or negative reactions before the market opens.
👍 160
Reply
4
Khan
Trusted Reader
1 day ago
Expert US stock margin analysis and operational efficiency metrics to identify companies with improving profitability. We track key performance indicators that often signal fundamental improvement before it shows up in earnings.
👍 128
Reply
5
Zaysha
Active Contributor
2 days ago
Missed it completely… sigh.
👍 276
Reply
© 2026 Market Analysis. All data is for informational purposes only.